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Abstract 
 
The selective α2-adrenoreceptor agonist, dexmedetomidine has shown 
neuroprotective, analgesic, anti-inflammatory and sympatholytic properties that may 
be beneficial in neonatal encephalopathy (NE). As therapeutic hypothermia is only 
partially effective, adjunct therapies are needed to optimize outcomes. The aim was 
to assess whether hypothermia+dexmedetomidine augments neuroprotection 
compared to routine treatment (hypothermia+fentanyl sedation) in a piglet model of 
NE using magnetic resonance spectroscopy (MRS) biomarkers, which predict 
outcome in babies with NE, and immunohistochemistry. After hypoxia-ischemia (HI), 
20 Large White male piglets were randomized to: (i) hypothermia+fentanyl with 
cooling to 33.5°C from 2-26h; or (ii) hypothermia+dexmedetomidine (loading dose 
2μg/kg at 10 minutes followed by 0.028μg/kg/h for 48h). Whole-brain phosphorus-31 
and regional proton MRS were acquired at baseline, 24 and 48 h after HI. At 48h, cell 
death (TUNEL) was evaluated over 7 brain regions.  Dexmedetomidine plasma 
levels were mainly within the target sedative range of 1 μg/L. In the 
hypothermia+dexmedetomidine group there were 6 cardiac arrests (3 were fatal) 
versus 2 (none fatal) in the hypothermia+fentanyl group. The 
hypothermia+dexmedetomidine group required more saline (p=0.005) to maintain 
blood pressure. Thalamic and white matter Lactate/N Acetyl aspartate did not differ 
between groups (p=0.66 and 0.21 respectively); whole brain nucleotide tri-phosphate 
(NTP)/epp was similar (p=0.73) over 48h. Cell death (TUNEL positive cells/mm2) was 
higher in the hypothermia+dexmedetomidine compared to the hypothermia+fentanyl 
group (mean counts 5.1 versus 2.3, difference 2.8 (95% C.I. 0.6 to 4.9), p=0.036). 
Hypothermia+dexmedetomidine was associated with adverse cardiovascular events 
even within the recommended clinical sedative plasma level; these may have been 
exacerbated by an interaction with either isoflurane or low body temperature. 
Hypothermia+dexmedetomidine was neurotoxic following HI in our piglet NE model, 
suggesting caution is vital if dexmedetomidine is combined with cooling following NE.  
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Introduction 
Intrapartum-related neonatal encephalopathy (NE) leads to a considerable global 
public health burden resulting in 50 million disability life adjusted years in babies who 
survive; in 2010 this related to 2.4% of the Global Burden of Disease and 6.1 million 
years of life with disability [1,2]. Therapeutic hypothermia reduced the combined rate 
of mortality and severe disability in moderate to severe NE with number needed to 
treat to avoid death and/or an adverse neurodevelopmental outcome of 6-7 in 
developed countries [3]. However despite cooling, around 50% of infants have 
adverse outcomes [4]. Effective and safe adjunct therapies are needed to augment 
hypothermic neuroprotection. 
 
Dexmedetomidine is a highly selective 2-adrenoceptor agonist that confers 
sedative, anti-inflammatory, analgesic, sympatholytic and organ-protective properties 
[5]. Pre-clinical [6] and clinical studies [7] show the importance of sedation during 
therapeutic hypothermia and recent data have shown the critical importance of the 
sensitizing effect of perinatal inflammation and infection in both high and low-income 
socio-economic groups [8-10]. There are concerns with the routine long-term use of 
opioids in neonates [11]. A sedative that enhances macrophage phagocytosis and 
bacterial clearance, minimizing inflammation-induced brain injury with no 
neurotoxicity would be particularly helpful in these patients.  
 
Dexmedetomidine has extensive experimental support for its neuroprotective effects 
by both 2 and non-2 adrenoceptor mediated mechanisms. Dexmedetomidine has 
shown neuroprotection in neonatal models of hypoxic-ischemic brain injury [12] and 
anesthetic brain injury in rodents [13]. Dexmedetomidine has a dose dependent anti-
inflammatory effect on plasma cytokine release following sepsis [14,15] and 
neuroprotective properties in sepsis-induced brain injury [16].  
 
Dexmedetomidine has been used as a sedative in critically ill children and neonates 
[17]. A dose dependent hemodynamic response has been seen with hypotension, 
hypertension and bradycardia particularly with increasing plasma concentrations [18-
20]. Dexmedetomidine effects may be opposing and depend on central and 
peripheral actions. Close monitoring of circulatory dynamics with dexmedetomidine 
has been recommended especially with therapeutic hypothermia where there is 
potential for altered pharmacokinetics (PK) and pharmacodynamics (PD) [21]. In our 
previous study, we investigated dexmedetomidine PK during hypothermia and 
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rewarming to determine the safe and effective dose for use in a study of 
neuroprotection after hypoxia-ischemia. We found reduced dexmedetomidine 
clearance due to cumulative effects of hypothermia and hypoxia-ischemia (HI). 
Indeed, dexmedetomidine clearance was reduced almost ten fold compared to adult 
values; PK analysis estimated a loading dose of 2 μg/kg dexmedetomidine followed 
by 0.028 μg/kg/h would achieve the sedative target plasma concentration of 0.5–0.6 
μg/l with hypothermia after HI [22]. 
 
We hypothesized that hypothermia+dexmedetomidine would lead to enhanced brain 
protection than hypothermia+fentanyl after global HI. Our aim was to assess whether 
an optimized dose of dexmedetomidine started 10 minutes after HI augments routine 
hypothermic neuroprotection in a piglet perinatal asphyxia model. This model also 
has strong similarities to newborn infants with NE in terms of the timing of the 
evolution of injury after HI [23,24], pattern of injury, neuropathology and cerebral 
magnetic resonance spectroscopy (MRS) [25]. The effectiveness of 
dexmedetomidine protection was assessed using: (i) Cerebral MRS biomarkers, 
proton (1H) MRS lactate/ N acetyl aspartate (NAA) [25] and phosphorus-31 (31P) 
MRS for phosphocreatine/inorganic phosphate (PCr/Pi) and nucleotide triphosphate 
(NTP)/ exchangeable phosphate pool (epp) [23]; and (ii) Histological assessment of 
cell death using TUNEL at 48h after hypoxia ischemia. 
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Material and Methods 
Sample size calculation 
Our primary outcomes were cerebral lactate/NAA and NTP/epp. Previous work with 
our model suggested that the change in lactate/NAA during 48h varied between 
normo- and hypothermic groups by 1.0 U, with a standard deviation of 0.65 U (log 
scale). Assuming a similar magnitude of additional effects for 
hypothermia+dexmedetomidine following HI versus hypothermia+fentanyl and similar 
variability at 48 h and with 5% significance and 80% power, at least eight subjects 
were required in each group based on a two-sample t-test sample size calculation. 
 
Animal experiments and surgical preparation 
All animal experiments were approved by the ethics committee of UCL and 
performed under UK Home Office Guidelines [Animals (Scientific procedures) Act, 
1986]. The study complies with the ARRIVE guidelines. Twenty newborn male piglets 
with a birth weight of 1.6-2.1kg <48 h of age were anaesthetized and surgically 
prepared as described previously [24].  The study timeline is shown in Figure 1.  
 
Following clinical assessment, piglets were sedated with intramuscular midazolam 
(0.2 mg/kg). Whilst monitoring arterial oxygen saturation (SpO2), anesthesia was 
induced by inhalation of isoflurane (4% v/v) through a facemask to facilitate 
tracheostomy and intubation. Throughout the surgery, isoflurane was maintained at 
2.8–3% guided by peripheral oxygen saturation monitoring (Nonin Medical, 
Plymouth, MN, USA) and the animal's response to stimulation. Following 
tracheostomy, a suitable size of endotracheal tube (Smiths Medical, Ashford, Kent, 
UK) was fixed and the piglet was mechanically ventilated (SLE 2000 infant 
Ventilator, Surrey, UK). Ventilator settings were adjusted to maintain partial pressure 
of oxygen (PaO2) at 8–13 kPa and carbon dioxide (PaCO2) at 4.5–6.5 kPa, allowing 
for temperature and fraction of inspired oxygen (FiO2) correction of the arterial blood 
sample. After the airway was secured, both common carotid arteries were surgically 
isolated at the level of the fourth cervical vertebra and a vascular occluder (OC2A, In 
Vivo Metric, Healdsburg, CA, USA) was placed on each side. After completion of 
surgery, inspired isoflurane concentration was maintained at 2% v/v. 
 
An umbilical venous catheter was inserted for infusion of maintenance fluids (10% 
dextrose, 60 ml/kg/day before the insult and 40 ml/ kg/day after resuscitation), 
fentanyl (5 μg/kg/h in the cooling group, and antibiotics (benzyl penicillin 50mg/kg, 
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every 12 h and gentamicin 4mg/kg, once a day). An umbilical arterial catheter was 
inserted for invasive physiologic monitoring (SA instruments) for heart rate and 
arterial blood pressure, and blood sampling for arterial gases and electrolytes (Abbot 
Laboratories, UK). Hepsal (0.5 IU/ml of heparin in 0.9% saline solution) was infused 
at 0.3 ml/h to prevent umbilical arterial catheter blockage. 
 
Piglets were cared for under intensive care conditions throughout the experiment. To 
maintain the MABP above 40mmHg, bolus infusions of 0.9% saline (Baxter; 10 
ml/kg), dopamine (5–20 μg/kg/min), dobutamine (5–20 μg/kg/min) and adrenaline 
(0.1–1.5 μg/kg/min) were used as required by a NICU trained clinician. High serum 
lactate was treated by optimizing oxygenation and 0.9% saline bolus infusions. 
Hyperkalemia (K>7.0 mmol/l) was treated with 4 μg/kg salbutamol (10 μg/ml) over 10 
minutes. 
 
MR methods 
The head was immobilized in a stereotactic frame for MRS acquisition. Piglets were 
positioned within the bore of 9.4 Tesla Agilent MR scanners. 1H and 31P MRS data 
were acquired at baseline and at 24 and 48h after cerebral HI. 
 
31P MRS 
A 7 cm x 5 cm elliptical transmit-receive MRS surface coil tuned to the 31P resonant 
frequency was positioned on top of the head. 31P MRS was acquired with 1-minute 
resolution using a non-localized single-pulse acquisition. MRS data were analyzed 
using the Advanced Method for Accurate, Robust and Efficient Spectral fitting of 
MRS data with use of prior knowledge (AMARES)[26] as implemented in the jMRUI 
software. Prior knowledge of NTP multiplet structure was used. NTP is predominately 
ATP and the latter contributes approximately 70% of the NTP signal [27]. Thus NTP 
changes during this experiment predominately reflected ATP changes. Pi was fitted 
using 4 separate components and PCr with a single component. The following peak-
area ratios were calculated: Pi/epp, PCr/epp, and NTP/epp where epp = 
exchangeable phosphate pool= Pi + PCr + 2γ-NTP + β-NTP. 
 
1HMRS 
1H MRS data were collected from voxels located in the dorsal right subcortical white 
matter at the centrum semiovale level (white matter voxel, 8 Å~ 8 Å~ 15mm) and in 
the deep gray matter centered on both lateral thalami (deep gray matter voxel, 15 Å~ 
15 Å~ 10mm) using a combination of a 65 Å~55mmelliptical receive surface coil, a 
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150mm diameter transmit volume coil and a LASER acquisition (TR = 5000 ms, TE = 
288 ms, 128 averages). Spectra were analyzed using AMARES as implemented 
in the jMRUI software and the lactate/NAA peak area ratio was calculated. 
 
Cerebral hypoxia ischemia  
31P MRS data were collected at baseline, during HI and for one hour after cessation 
of HI. HI was induced inside the MR scanner by remotely inflating the vascular 
occluders around both common-carotid arteries, and simultaneously reducing FiO2 
to 6% (vol/vol). During HI the β-NTP peak height was continuously monitored using 
in-house Matlab (Mathworks) software. At the point at which β-NTP had fallen to 50% 
of its baseline value, FiO2 was increased to 9%. When β-NTP fell to 40% baseline 
height the inspired oxygen fraction was titrated to keep the β-NTP peak height 
between 30% and 40% of its original height for a period of 12.5 min. At the end of HI 
the carotid arteries were de-occluded and the FiO2 returned to 21%. 
 
Experimental groups 
Following transient HI and after resuscitation, piglets were randomized by computer 
generated randomization to: (i) hypothermia+fentanyl throughout the study n=10 or 
(ii) hypothermia+dexmedetomidine n=10. A loading dose of 2 μg/kg 
dexmedetomidine was started at 10 minutes after resuscitation and infused over 20 
minutes followed by a maintenance dose at 0.028 μg/kg/h for the next 48 h. Fentanyl 
was stopped upon starting maintenance dexmedetomidine. Blood for 
dexmedetomidine PK assay was sampled at 10, 20, 40 and 60 minutes and 
thereafter at 2, 4, 6, 12, 24, 36 and 48h after HI. Both groups were cared for over 48h 
after HI and maintained hypothermic (core temperature 33.5°C) between 2–26h.  
 
Amplitude integrated EEG (aEEG) 
After surgical preparation, multichannel six-lead EEG monitoring (Nicolet Care 
Fusion, Wisconsin, USA) was recorded at baseline and throughout the periods 
between MRS data acquisitions. Filtered amplitude integrated EEG (aEEG) 
recordings were classified according to the voltage criteria [28]. Grade 1 was 
severely abnormal voltage with lower and upper margin of the bandwidth <5µV and 
<10 µV respectively, grade 2 lower margin and upper margin <5 µV and >10 µV 
respectively and grade 3 lower and upper margin >5 µV and >10 µV respectively. 
  
Brain histology 
At 48h after HI, piglets were euthanized with pentobarbital, the brain was fixed by 
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cardiac perfusion with cold 4% paraformaldehyde, disected out and post-fixed at 4 °C 
in 2% paraformaldehyde for 7 days. Coronal slices (5 mm thick) of the right 
hemisphere, starting from anterior to the optic chiasma, were embedded in paraffin, 
sectioned to 8-μm thickness and stained with hematoxylin and eosin to validate the 
bregma for analysis. For each animal and brain region, TUNEL-positive nuclei were 
counted at two levels, from 7 regions (3 fields per region) by an investigator blind to 
the treatment group and the average counts per field of view converted into counts 
per mm2 (Figure 2). 
 
To assess cell death, brain sections were stained for nuclear DNA fragmentation 
using histochemistry with transferase mediated biotinylated d-UTP nick end-labeling 
(TUNEL) as previously described [29]. Briefly, TUNEL sections were pretreated in 
3% hydrogen peroxide, subjected to a protease K pre-digestion (Promega, 
Southampton, UK) and incubated with TUNEL solution (Roche, Burgess Hill, UK). 
TUNEL was visualized using avidin-biotinylated horseradish complex (ABC, Vector 
Laboratories, Peterborough, UK) and diaminobenzidine/ H2O2 (DAB, Sigma, Poole, 
UK) enhanced with CoSO4 and NiCl2. TUNEL sections were dehydrated and cover-
slipped with DPX (VWR, Leighton Buzzard, UK).  
 
Statistical Methods 
Physiological variables 
The mean level of physiological measurements for the two treatment groups were 
compared by firstly taking the average of the results taken at 15 minute intervals in 
the following periods; baseline, T=0, 2-3.5h, 3.75-26h and 26.25-48h for each 
subject.  Analysis of variance was then performed on the least significant (LS) means 
fitting terms Treatment, Period and a Treatment x Period interaction.  The means for 
each period and differences in means for the two treatments were presented with 
confidence intervals in Table 2.  
 
MRS 
All analyses were performed using the SAS JMP® v11.0.0 software. A statistical 
model was fitted to the ratios NTP/epp, PCr/Pi and Lac/NAA. An analysis of variance 
(ANOVA) model was fitted and the differences in the means on the log scale for the 
two treatment groups (hypothermia+dexmedetomidine versus hypothermia+fentanyl) 
were estimated from the model at each of the three time points with 95% confidence 
interval (CI) for the differences. The differences in treatment group means are shown 
graphically using 95% Least Significant Difference error bars.  
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aEEG 
Following the baseline scoring, scores were assigned at 3, 6, 12, 24 and 36h after HI 
and group averages compared.  
 
TUNEL 
An analysis of variance model was fitted to the mean counts to give an estimate of 
the expected counts per mm2. The overall difference between the means for the two 
treatment groups, and treatment differences across regions are presented with 95% 
CI and graphically using 95% Least Significant Difference error bars. 
 
Pharmacokinetics 
A one compartment linear disposition model was used to fit earlier data to the PK 
model [22]. Population parameter estimates were obtained using non-linear mixed 
effects modelling (NONMEM VII, Icon Development Solutions, Elliot City, MD, USA) 
[30]. This model accounts for population parameter variability (between subjects) and 
residual variability (random effects) as well as parameter differences predicted by 
covariates (fixed effects). A visual predictive check (VPC) [31], a modeling tool that 
estimates the concentration prediction intervals and graphically superimposes these 
intervals on observed concentrations after a standardized dose, was used to 
ascertain if current observed concentrations were predicted by parameter estimates 
from that earlier study [22,32]. Concentration prediction intervals from the earlier 
study were graphically superimposed on those intervals determined from observed 
concentrations in the current study. Simulation is performed with parameter 
estimates from the earlier study using 1000 subjects with characteristics taken from 
new patients. For data such as these where covariates such as dose, weight and 
height are different for each patient, a prediction corrected visual predictive check 
[33] is used; observations and simulations are multiplied by the population baseline 
value divided by the individual-estimated baseline.  
 
Results 
There were 10 animals in each group.   
Baseline Physiological Data and Insult severity  
There were no intergroup differences in postnatal age, bodyweight, duration of 
hypoxia-ischemia and insult severity measured by acute energy depletion (AED) on 
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31P MRS (Table 1). The baseline blood gas CO2 was lower (p=0.033, but still within 
the normal range) and blood lactate higher (p=0.002) in the 
hypothermia+dexmedetomidine group compared to the hypothermia+fentanyl group 
(Table 2). Baseline mean arterial blood pressure (MAP), heart rate, oxygen 
saturation, arterial blood gas oxygen, base excess, glucose, blood pH and core body 
temperature were similar between groups (Table 2). The baseline oxygen was higher 
in the dexmedetomidine and cooling group but similar for other time epochs.  
 
Just after resuscitation, the hypothermia+fentanyl group had a lower oxygen 
saturation compared to the hypothermia+dexmedetomidine group (p=0.044); in the 
time periods 2-3.5h and 26-48h, the blood gas oxygen partial pressure was higher in 
the hypothermia+fentanyl group compared to the hypothermia+dexmedetomidine 
group (p=0.032 and 0.029 respectively). In the period 2-3.5h after HI, the 
temperature was lower in the hypothermia+dexmedetomidine group compared to the 
hypothermia+fentanyl group (p=0.027). There was weak evidence for a lower MAP in 
the hypothermia+dexmedetomidine group compared to the hypothermia+fentanyl 
group between 26-48h (p=0.071). 
 
The fluid and inotrope requirement comparison between groups is shown in Table 3 
and 4). Comparing hypothermia+dexmedetomidine to hypothermia+fentanyl groups, 
5/10 versus 1/10 subjects required noradrenaline, 4/10 versus 2/10 subjects required 
adrenaline for MBP support, 7/10 versus 3/10 subjects required adrenaline for 
resuscitation, 6/10 versus 2/10 subjects had a cardiac arrest, 3/10 versus 0/10 
subjects had a fatal cardiac arrest. More saline was required for blood pressure 
support in the hypothermia+dexmedetomidine group compared to the 
hypothermia+fentanyl group (p=0.005).  
 
MRS analysis 
The least squares means plots and 95% Least Significant Difference (LSD) bars for 
NTP/epp, PCr/Pi and Lac/NAA (on log 10 scale) in thalamus and white matter are 
shown in Figure 3. The differences in the means and CI at 48h are shown in Table 
5. There was no difference at 48h between groups for any of the MRS peak area 
ratios. There was weak evidence that the hypothermia+dexmedetomidine group 
brain NTP/epp was lower than hypothermia+fentanyl (p=0.05) at 24h, but at 48h this 
difference was not observed.  
 
EEG 
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There was no difference between the group mean aEEG scores at any time point for 
the hypothermia+fentanyl compared to the hypothermia+dexmedetomidine groups 
(Figure 4). 
 
Hypothermia+ dexmedetomidine increased TUNEL positive cell counts 
Representative photomicrographs of TUNEL staining in the putamen and 
periventricular are shown in Figure 5A. A paired t-test comparing the overall TUNEL 
count means (across all fields and subjects) of the two treatment groups for each of 
the 7 regions and overall was performed (Table 6).  There was evidence of a 
difference between treatment groups (p=0.036) (Figure 5B) with 
hypothermia+dexmedetomidine with more TUNEL positive cells/mm2 than 
hypothermia+fentanyl. The overall mean count for the 
hypothermia+dexmedetomidine group was 5.1 compared with a mean count of 2.3 
for the hypothermia+fentanyl; a mean difference of 2.8 (95% CI 0.6-4.9). The 
regional brain counts for the two groups are shown in Figure 5C.  
 
Dexmedetomidine PK  
The mean plasma concentrations of dexmedetomidine following a loading dose of 2 
μg/kg over 20 minutes followed by an infusion of 0.028 μg/kg/h were below 1 μg/L, 
despite the model predicting slightly higher concentrations (Figure 6). Figure 6A 
shows prediction corrected observed concentrations. Figure 6B shows prediction 
corrected percentiles (10%, 50%, 90%) for observations (red lines with symbols) and 
predictions (lines) with 95% confidence intervals for prediction percentiles (grey 
shaded areas). The median predictions and observations graphically lie almost on 
top of each other. The dexmedetomidine plasma concentrations (observations) were 
as predicted and mainly within the clinical sedative range of <1 μg/L. 
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Discussion 
Compared to routine hypothermia+ fentanyl sedation after HI, we did not observe any 
improvement in cerebral protection based on magnetic resonance biomarkers 
lactate/NAA and NTP/epp with hypothermia+dexmedetomidine. There was increased 
cell death across the combined 7 brain regions with hypothermia+ dexmedetomidine 
compared to hypothermia+fentanyl. All piglets were anesthetized with isoflurane, 
which may have exacerbated the cardiovascular effects. The 
hypothermia+dexmedetomidine group required more saline for MBP support than the 
hypothermia+fentanyl group and there were three fatal cardiac arrests in the 
hypothermia+dexmedetomidine versus none in the hypothermia+fentanyl group. 
These effects occurred despite dexmedetomidine plasma levels within target 
sedative range of 1 μg/L.  
 
In preparation for this study, we had previously studied the PK of dexmedetomidine 
in the piglet [22]; compared with adult values, clearance was reduced almost tenfold 
in the newborn piglet following hypoxic ischemic brain injury and subsequent 
therapeutic hypothermia. This reduced clearance was related to cumulative effects of 
both hypothermia and exposure to hypoxia. We observed that high plasma 
concentrations of dexmedetomidine were associated with major cardiovascular 
complications and were able to estimate from a one compartment model, that a bolus 
of 2 μg/kg dexmedetomidine over 20 min followed by an infusion of 0.028 μg/kg/h 
dexmedetomidine during therapeutic hypothermia would likely achieve a plasma 
concentration of 0.5–0.6 μg/L (this is the concentration associated with safe sedation 
in human newborns [34]). In the current study, despite achieving plasma 
concentrations mainly < 1 μg/L with the calculated infusion rate, we saw adverse 
cardiovascular responses; there was no relation between the plasma concentration 
and adverse cardiovascular responses.  
 
The baseline physiological data showed a lower CO2 partial pressure and higher 
lactate concentration in the blood of the hypothermia+dexmedetomidine group 
compared to the hypothermia+fentanyl group, however all other variables were 
similar at baseline and these differences were not apparent at later time points in the 
study. The severity of the hypoxic ischemic insult was similar between groups.  Mean 
partial pressure oxygen (PaO2) was lower in the hypothermia+dexmedetomidine 
group compared to the hypothermia+fentanyl group at 2-3.5h and 26-48h; this may 
reflect the cardiovascular and hemodynamic instability observed in the 
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hypothermia+dexmedetomidine group.  
 
Many of the properties of dexmedetomidine, including sedation are transduced via 
2-adrenoceptor signaling. The 2 receptors are located in blood vessels, 
sympathetic terminals and the brain, where their activation causes vasoconstriction, 
anxiolysis, sedation and analgesia. Dexmedetomidine is 1600 times more specific to 
α2 than α1 receptors, permitting its use for sedation without cardiovascular side 
effects of α1 receptor activation [19]. Dexmedetomidine stands out from other 
sedatives including opioids for its minimal respiratory depression, anti shivering effect 
and prevention of opioid induced muscle rigidity [35].. The hemodynamic changes 
and requirement for MBP support we saw in our study can be explained by the 
properties of dexmedetomidine: in the central nervous system dexmedetomidine 
produces sympatholysis and a reduction in blood pressure, in the peripheral nervous 
system it causes vasoconstriction leading to an increase in blood pressure.  
A recent phase II/III multicenter, safety and pharmacokinetic study of 
dexmedetomidine in term and preterm infants (>28-<44 weeks gestation) 
(predominantly those intubated following surgery) suggested that dexmedetomidine 
is effective for sedating preterm and full-term neonates and is well-tolerated without 
major adverse events [36]. There were three adverse events observed (hypo and 
hypertension and agitation). The PK profile of dexmedetomidine was different in 
neonates compared with older children with a longer half-life and larger area under 
the curve drug concentration over time; this confirms our previous findings in the 
piglet indicating that lower doses are required to achieve the same levels of sedation 
and avoid adverse effects with newborns. In other clinical studies, bradycardia, 
hypotension and hypertension have been observed in children to varying degrees 
depending on the plasma concentration of dexmedetomidine [34,37,38]. In our study 
the combination of immaturity, HI, hypothermia and the concomitant use of isoflurane 
are likely to have increased the risk of adverse effects from dexmedetomidine 
despite plasma levels mainly less than 1 μg/L. However, further work is needed 
before our results are extrapolated to humans as some recent studies suggest 
beneficial effects with dexmedetomidine: in 102 patients receiving dexmedetomidine 
during the first postoperative day after cardiac surgery compared to an age- and 
procedure-matched cohort not receiving dexmedetomidine, the use of a 
dexmedetomidine infusion was associated with a decreased incidence of acute 
kidney injury but no change in clinical outcomes [39]. In a retrospective cohort study 
of infants undergoing surgical intervention for congenital heart defects requiring 
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cardiopulmonary bypass, the use of dexmedetomidine in the operating room at the 
time of sternal closure was associated with reduced need for mechanical ventilation 
in the immediate postoperative period. No increased adverse outcomes were 
reported in these infants, despite exposure to deep hypothermic circulatory arrest 
and intraoperative fentanyl [40]. 
   
There are counteracting and complex interactions between α2- agonist and α2- 
adrenoreceptor subtypes which may be affected by hypothermia. The 2-adrenergic 
receptors present in the brainstem decrease blood pressure; activation of 
presynaptic α2A- adrenoreceptors decreases sympathetic outflow and norepinephrine 
release causing hypotension and bradycardia [41-43]. Postsynaptic α2B- 
adrenoreceptors on vascular smooth muscle mediate vasoconstriction and are 
responsible for hypertension. Presynaptic α2C- adrenoreceptors are also inhibitory 
autoreceptors with a prominent role in peripheral autonomic system [44]; these 
receptors are sensitive to temperature and become active at temperatures below 
37°C [45].  All piglets in our study were cooled from 2-26h after HI and the adverse 
cardiovascular effects (cardiac arrest) may be due to the combination of 
hypothermia+dexmedetomidine. We did not assess the effect of dexmedetomidine 
without hypothermia, as cooling is routine therapy for moderate to severe NE. 
Cooling has the potential to change the expression of α2C- receptors; silent 
intracellular α2C- receptors become active and translocate to the cell surface causing 
vasoconstriction following exposure to temperatures below 37°C [45]. Therapeutic 
hypothermia-related bradycardia has been reported in young children following 
dexmedetomidine infusion [35,46]. Furthermore, it is known that dexmedetomidine 
interferes with thermoregulation and promotes hypothermia itself [47,48]. This may 
explain our observation of a significantly lower body temperature between 2-3.5h in 
the hypothermia+dexmedetomdine group, although this was not below the target 
hypothermia therapeutic range. We have previously shown that the depth of 
hypothermia is critical for its efficacy in this model [49].  
 
It has been shown that anesthesia influences the hemodynamic effects of 
dexmedetomidine. In anesthetized patients with depressed sympathetic tone, 
dexmedetomidine increased MAP by peripheral vasoconstriction whereas in awake 
patients with intact tone, it decreased MAP via centrally mediated effect of α2 
agonists [50]. Rapid dexmedetomidine injection in a group of young children during 
isoflurane anesthesia for cardiac catheterization transiently increased systolic and 
diastolic blood pressure [51]. All piglets in our study were anesthetized with 
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isoflurane throughout the experiments. Inhaled isoflurane dose has been shown to 
reduce cardiac output and systemic vascular resistance [52]. The negative inotropic 
and peripheral vasodilatation effects of isoflurane are likely to augment the effects of 
dexmedetomidine on cardiac output and may have added to the adverse 
cardiovascular responses in our piglets receiving dexmedetomidine. Isoflurane 
anesthetized dogs and cats developed greater negative cardiovascular effects with 
dexmedetomidine as an adjunct compared to isoflurane only anesthesia [53,54] 
Dexmedetomidine reduces cardiac output and the subsequent redistribution of blood 
flow limits hepatic and other non-vital organ perfusion [55]; this in turn reduces 
hepatic blood flow and hydroxylation and clearance [56,57]. In our piglets, it is likely 
that the interaction between dexmedetomidine and isoflurane anesthesia (negative 
inotropic effect and vasodilation) are likely to have increased the depression of the 
sympathetic activity [58] by the variable binding to peripheral and central α2 
adrenergic receptors [59].  
 
There are conflicting reports of neuroprotection and neurotoxicity with 
dexmedetomidine and clonidine (an α2 adrenoceptor agonist approximately eight-
times less selective towards the α2 adrenoceptor than dexmedetomidine). The effect 
of acute (25 μg/kg) or prolonged (25 μg/kg three times daily, for 2d or 4d) exposure 
of dexmedetomidine with therapeutic hypothermia on uninjured neonatal Lewis rats 
was studied. Prolonged dexmedetomidine treatment in neonatal rats was not 
associated with abnormal brain histology (no increased gliosis, macrophage 
activation, or apoptosis in either hypothermic or control rats).  Although no adverse 
effects were seen, these were not injured animals, nor did they have fentanyl and 
isoflurane exposure [60]. Other rodent studies have shown that dexmedetomidine 
protects the brain against focal [61,62] and global [63,64] HI by inducing anti-
apoptotic effects [65,66]} or via α2 adrenergic and imidazole 1 receptors [12]. In the 
developing mouse brain there was dose dependent neuroprotection with 
dexmedetomidine and clonidine [67]. Further studies however have shown that 
dexmedetomidine and clonidine induce cerebral hypoperfusion and neurotoxicity in 
small animal stroke models [68]. Dean et al showed a complex dose dependent 
response to clonidine with low dose but not high dose being neuroprotective after 
hypoxic brain injury in preterm fetal sheep [69]. We observed the combination of 
hypothermia+dexmedetomidine to be neurotoxic with increased TUNEL positive cells 
(5.1 versus 2.3/mm2 mean counts across the brain) compared to 
hypothermia+fentanyl. One mechanism leading to this in our model could be a 
reduction in cerebral blood flow by vasoconstriction in pial arteries and veins [70]. 
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Studies in rats and dogs demonstrated dexmedetomidine dose dependently caused 
vasoconstriction in pial arteries mediated either by direct action on α2- 
adrenoreceptors [71] on the small cerebral arteries distal to circle of Willis [71]. Other 
studies have shown that systemic dexmedetomidine indirectly induces cerebral 
vasoconstriction by reducing cerebral oxygen consumption [70].  
 
The reasons for these conflicting reports may be related to differences in species, 
models, maturity of the brain, dose and timing of the drugs and the integrity of the 
autonomic system. Different expressions of α- adrenoreceptor subtypes in cerebral 
arteries in human, monkeys and dogs can lead to different responses to 
noradrenaline, α2- agonists and antagonists...An age dependent change in 
expression and binding capacity of α2- receptors in postnatal life occurs in human 
and rat brain and this may affect the sensitivity of the newborn to dexmedetomidine 
[72] . 
Our study suggests that caution is needed when considering the use of 
dexmedetomidine with hypothermia in the newborn after HI. We saw no improvement 
in cerebral energetics on MRS with hypothermia+dexmedetomidine versus 
hypothermia+fentanyl. There was evidence of neurotoxocity with an increased 
number of TUNEL positive cells across the brain with hypothermia+dexmedetomidine 
compared to hypothermia+fentanyl. We saw some expected hemodynamic effects of 
dexmedetomidine; adverse effects and cardiac arrests may relate to interactions 
between reduced clearance in an immature animal, concomitant anesthesia 
exacerbating the cardiovascular effects of dexmedetomidine and the effects of 
hypothermia on the temperature sensitive α2C- receptors. Reduced cerebral perfusion 
induced by dexmedetomidine is likely to have contributed to the neurotoxicity.   
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Table 1. Baseline group data  
 
Population 
variables 
Hypothermia +  
Fentanyl         
Mean (SD) 
Hypothermia + 
Dexmedetomidine 
Mean (SD) 
P value 
 
Postnatal age (h) 32.8 (10.4) 33.0 (10.0) 0.51 
Body weight (g) 1978 (109) 1900 (190) 0.247 
Duration of HI 
(min) 
23.6 (3.04) 25.4 (5.56) 0.4 
Insult severity  
(x10-2) measured 
from acute energy 
depletion (AED)* 
9.63 (3.2) 10.6 (3.3) 0.53 
*The insult severity AED was estimated by calculating the time integral of the change in 
NTP/epp during HI and the first 60 min of resuscitation
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Table 2. Means and Differences in Physiological Variables pooled according to Time Period after HI 
 
 Period LS Mean SEM LS Mean SEM Difference  
LS Mean 
 
SED Lower CL Upper CL p-Value 
  Control Dexmedatomidine Control cf Dex     
MAP Baseline 51.9 2.74 50.3 2.74 1.66 3.88 -6.04 9.37 0.669 
 T=0 47.6 2.74 42.8 2.74 4.80 3.88 -2.91 12.51 0.219 
 2 - 3.5h 43.0 2.74 43.9 2.74 -0.91 3.88 -8.62 6.79 0.814 
 3.5 - 26h 46.4 2.74 43.0 2.74 3.39 3.88 -4.32 11.10 0.384 
 26 - 48h 53.4 2.74 46.1 2.89 7.28 3.99 -0.64 15.20 0.071 
HR Baseline 176.6 7.43 171.1 7.43 5.52 10.51 -15.35 26.40 0.600 
 T=0 185.3 7.43 172.1 7.43 13.20 10.51 -7.67 34.07 0.212 
 2 - 3.5h 158.1 7.43 148.0 7.43 10.09 10.51 -10.79 30.96 0.340 
 3.5 - 26h 152.4 7.43 162.6 7.43 -10.14 10.51 -31.01 10.74 0.337 
 26 - 48h 175.9 7.43 179.8 7.83 -3.84 10.79 -25.29 17.60 0.723 
O2 Sat Baseline 98.0 1.67 98.3 1.67 -0.25 2.36 -4.94 4.44 0.916 
% T=0 83.7 1.67 88.7 1.76 -4.97 2.42 -9.78 -0.15 0.044 
 2 - 3.5h 99.0 1.67 98.8 1.67 0.20 2.36 -4.49 4.89 0.933 
 35 - 26h 98.4 1.67 98.4 1.67 -0.01 2.36 -4.70 4.68 0.998 
 26 - 48h 98.7 1.67 98.1 1.87 0.59 2.50 -4.39 5.56 0.815 
PaCO2 Baseline 6.5 0.51 5.0 0.47 1.52 0.70 0.12 2.91 0.033 
 T=0 5.4 0.40 5.2 0.44 0.23 0.60 -0.96 1.41 0.707 
 2 - 3.5h 4.2 0.44 3.9 0.40 0.29 0.60 -0.89 1.48 0.624 
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 3.5 - 26h 5.5 0.40 4.9 0.40 0.58 0.56 -0.54 1.70 0.304 
 26 - 48h 6.5 0.40 6.1 0.42 0.39 0.58 -0.75 1.54 0.496 
PaO2 Baseline 13.3 2.96 11.1 2.74 2.17 4.04 -5.87 10.21 0.592 
 T=0 8.9 2.30 8.6 2.57 0.36 3.44 -6.50 7.21 0.918 
 2 - 3.5h 21.0 2.57 13.5 2.30 7.51 3.44 0.65 14.36 0.032 
 3.5 - 26h 15.9 2.30 13.6 2.30 2.27 3.25 -4.19 8.74 0.486 
 26 - 48h 25.2 2.30 17.8 2.42 7.41 3.34 0.77 14.05 0.029 
BE Baseline 2.5 1.73 0.8 1.60 1.71 2.36 -2.98 6.41 0.469 
 T=0 -5.1 1.34 -4.5 1.50 -0.60 2.01 -4.60 3.40 0.766 
 2 - 3.5h 5.5 1.50 3.9 1.34 1.60 2.01 -2.40 5.60 0.428 
 3.5 - 26h 1.4 1.34 -1.0 1.34 2.38 1.89 -1.39 6.16 0.212 
 26 - 48h 1.3 1.34 -1.3 1.41 2.61 1.95 -1.27 6.48 0.185 
Lac Baseline 2.8 0.82 6.3 0.76 -3.50 1.12 -5.72 -1.28 0.002 
 T=0 8.8 0.63 8.8 0.71 0.06 0.95 -1.84 1.95 0.954 
 2 - 3.5h 4.6 0.71 4.9 0.63 -0.35 0.95 -2.25 1.54 0.713 
 3.5 - 26h 3.4 0.63 4.7 0.63 -1.24 0.90 -3.03 0.55 0.171 
 26 - 48h 2.6 0.63 3.2 0.67 -0.66 0.92 -2.49 1.18 0.478 
Glu Baseline 6.9 2.22 8.1 2.02 -1.23 3.00 -7.21 4.75 0.682 
 T=0 10.4 1.65 9.8 1.75 0.64 2.41 -4.16 5.43 0.792 
 2 - 3.5h 9.3 1.65 9.6 1.57 -0.28 2.28 -4.81 4.26 0.903 
 3.5 - 26h 12.7 1.57 16.3 1.57 -3.62 2.22 -8.04 0.79 0.107 
 26 - 48h 12.2 1.57 14.5 1.65 -2.30 2.28 -6.84 2.24 0.316 
pH Baseline 7.4 0.04 7.4 0.04 -0.07 0.06 -0.19 0.05 0.232 
 T=0 7.3 0.03 7.3 0.04 -0.02 0.05 -0.12 0.08 0.679 
 20 
 2 - 3.5h 7.6 0.04 7.6 0.03 -0.01 0.05 -0.11 0.09 0.836 
 3.5 - 26h 7.4 0.03 7.4 0.03 0.00 0.05 -0.10 0.09 0.930 
 26 - 48h 7.3 0.03 7.3 0.04 0.01 0.05 -0.09 0.11 0.849 
ToC Baseline 38.3 0.22 38.2 0.22 0.10 0.31 -0.52 0.71 0.753 
 T=0 37.8 0.22 37.9 0.22 -0.13 0.31 -0.74 0.48 0.654 
 2 - 3.5h 36.0 0.22 35.4 0.22 0.69 0.31 0.08 1.31 0.027 
 3.5 - 26h 33.6 0.22 33.5 0.22 0.13 0.31 -0.48 0.75 0.667 
 26 - 48h 37.3 0.22 37.2 0.22 0.09 0.32 -0.54 0.72 0.787 
MAP: mean arterial blood pressure mm Hg; HR: heart rate bpm; O2 saturation: oxygen saturation, PaO2: partial pressure of oxygen kPa; PaCO2: partial pressure of CO2 kPa; 
BE: base excess mmol/L; Lac: lactate; Glu: glucose mmol/L; pH: blood pH; T oC: core temperature. 
 Significant p values are in bold.  
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Table 3. Saline, inotrope (dopamine, dobutamine, noradrenaline and adrenaline) requirements and number of subjects 
requiring adrenaline for resuscitation, and number of cardiac arrests (fatal and non-fatal) 
 
Treatment/ pig Saline 
ml/kg/h 
Dopamine 
ug/ml/min 
Dobutamine 
ug/ml/min 
*Nor-adrenaline 
ng/ ml/ min 
*Adrenaline 
ng/ml/ min 
*Adrenaline 
for resus 
*Cardiac 
arrests 
*Fatal Cardiac 
arrests 
         
HT+fentanyl 294 0.947 16.1 10.55 84.56 131 1 1 0 
HT+fentanyl 301 0.64 38.5 0 0 0 1 0 0 
HT+fentanyl 308 0.689 20.1 2.32 0 0 0 0 0 
HT+fentanyl 312 0.625 28.1 2.43 0 0 1 1 0 
HT+fentanyl 314 1.041 12.27 0 0 0 0 0 0 
HT+fentanyl 316 0.416 2.13 0 0 0 0 0 0 
HT+fentanyl 317 0.74 2.39 3.02 0 0 0 0 0 
HT+fentanyl 327 0.208 6.77 0 0 0 0 0 0 
HT+fentanyl 330 0.208 23.04 0 0 0 0 0 0 
HT+fentanyl 337 0.631 21.4 7.36 0 386.3 0 0 0 
HT+dexmedetomidine 299 0.869 0 0 0 0 0 0 0 
HT+dexmedetomidine 302 1.03 17.39 0 0 0 2 1 0 
HT+dexmedetomidine 303 0.52 20.83 3.99 17.2 0 1 0 0 
HT+dexmedetomidine 304 1.15 17.7 4.82 79.3 0 0 0 0 
HT+dexmedetomidine 322 1.29 22.9 0 100 0 0 0 0 
HT+dexmedetomidine 323 1.7 5.9 0 15.15 159.5 1 1 0 
HT+dexmedetomidine 325 0.94 16.7 4.87 0 241 1 1 1 
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HT+dexmedetomidine 328 0.947 18.07 0 0 213 0 0 0 
HT+dexmedetomidine 313 2.22 23.6 7.36 172 181 1 1 1 
HT+dexmedetomidine 331 1.09 14.93 0 0 0 1 2 1 
 *1/10 vs 5/10 *2/10 vs 4/10 *3/10 vs 7/10 *2/10 vs 6/10 *0/10 vs 3/10 
p = 0.07 p = 0.31 p =  0.089 p = 0.085 p = 0.105 
HT: hypothermia.   
* Comparison of proportions of subjects with the complication or receiving the therapy (not appropriate to average over so many zeros) 
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Table 4. Least square mean and confidence limits for the total dose throughout the study of saline, dopamine and 
dobutamine treatment in the hypothermia+dexmedetomidine versus hypothermia+fentanyl groups 
 
 
 Control Dex  Confidence 
limits 
 
 LS 
mean 
SE
M 
LS 
mean 
SE
M 
Control - 
Dex 
SE
D lower  Upper p value 
Saline ml/ kg/ h 0.61 0.12 1.18 0.12 -0.56 0.17 -0.93 -0.20 0.005 
Dopamine 
µg/ml/min 17.1 3.1 15.8 3.1 1.3 4.4 -7.9 10.4 0.773 
Dobutamine 
µg/ml/min 2.6 1.0 2.1 1.0 0.5 1.5 -2.6 3.5 0.755 
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Table 5. Summary of differences between hypothermia+fentanyl and 
hypothermia+dexmedetomidine MRS data at 48h. 
 
 
Difference in 
Means (log 10) 
hypothermia+fent
anyl versus 
hypothermia+ 
dexmedetomidine 
95% C.I. for 
Difference 
(log scale) 
Ratio of 
Means 
(original 
scale) 
95% C.I. for 
Ratio 
(original 
scale) 
P value 
NTP/epp 
 -0.024 
-0.16 to 
0.12 0.95 0.69 to 1.3 0.73 
PCr/Pi 
 0.067 
-0.19 to 
0.32 1.17 0.65 to 2.1 0.60 
Thalamus 
Lac/NAA 0.101 
-0.37 to 
0.57 1.26 0.43 to 3.7 0.66 
White 
Matter 
Lac/NAA 0.345 -0.2 to 0.89 2.21 0.63 to 7.71 0.21 
 
The hypothermia+dexmedetomidine group showed no evidence of a difference compared to 
hypothermia +fentanyl. epp = exchangeable phosphate pool; PCr= phosphocreatine; Pi= 
inorganic phosphate; Lac= lactate; NAA= N acetyl aspartate 
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Table 6. Summary of Differences between hypothermia+fentanyl and 
hypothermia+dexmedetomidine TUNEL counts for seven brain regions and overall. 
 
Area Difference in Mean 
TUNEL Count 
(hypothermia+fentanyl 
versus hypothermia+ 
dexmedetomidine) 
Standard 
Error of 
the 
difference 
Lower 95% 
C.I. for 
Difference 
Upper 95% 
C.I. for 
Difference 
p value 
Sensorimotor 
cortex 
3.33 3.46 -3.52 10.19 0.337 
Cingulate 
cortex 
-1.04 3.46 -7.90 5.82 0.764 
Thalamus 
 
1.05 3.46 -5.81 7.91 0.762 
Caudate 
 
4.23 3.46 -2.63 11.08 0.225 
Putamen 
 
6.20 3.46 -0.66 13.06 0.076 
Internal 
Capsule 
2.69 3.60 -4.43 9.81 0.456 
Periventricular 
white matter 
3.11 3.46 -3.75 9.96 0.371 
OVERALL 
 
2.79 1.32 0.19 5.40 0.036 
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Figure Legends 
Figure 1 
Study time-line. Following baseline data acquisition, piglets underwent cerebral hypoxia-
ischaemia. At the end of hypoxia-ischemia (time 0), piglets were randomized to (i) 
hypothermia (33.5oC for 24h from 2-26h)+fentanyl or (ii) hypothermia+dexmedetomidine. For 
those randomized to hypothermia+fentanyl, the fentanyl infusion was continued. For those 
randomized to hypothermia+dexmedetomidine, fentanyl was stopped and a loading dose of 
2μg/kg dexmedetomidine was started at 10 mins after resuscitation and infused over 20 mins 
followed by a maintenance dose at 0.028 μg/kg/h for the next 48 h. The time points for the 
dexmedetomidine PK blood concentrations are shown. Blood gases were done every 4-6h 
and more frequently if unstable.  
 
Figure 2 
Representative piglet brain photomicrographs at the 2 brain levels indicating brain regions 
assessed for TUNEL immunohistochemistry. (1) cingulate cortex, (2) sensorimotor cortex, (3) 
periventricular white matter. (4) internal capsule, (5) caudate nucleus, (6),putamen (7) 
thalamus. Three fields per region were assessed on 2 brain levels. Red fields indicate those 
brain regions included in the MRS voxel; black fields indicate those brain regions not included 
in the MRS voxel.  
 
Figure 3 
Magnetic resonance spectroscopy peak area ratios of the brain at baseline, 24 and 48h after 
HI. Least square mean plots with 95% least significant difference (LSD) bars for the NTP/epp 
and PCr/Pi in whole forebrain and Lac/NAA in thalamus and white matter; non overlapping 
bars show evidence of a significant difference. There was no difference at 48h between 
groups for any of the MRS peak area ratios. At 24h, hypothermia+dexmedetomidine NTP/epp 
was lower than hypothermia+fentanyl (p=0.05), but at 48h this difference was not observed.  
HI: hypoxia ischaemia; NTP: nucleotide triphosphate; epp: exchangeable phosphate pool.  
 
Figure 4 
A. Amplitude-integrated electroencephalogram (aEEG). There was no difference between the 
hypothermia+dexmedetomidine compared to the hypothermia+fentanyl group mean aEEG 
scores at any timepoint after hypoxia ischemia. B. The classification criteria used to define 
the aEEG group.  
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Figure 5 
TUNEL histology. A. Representative sections are shown at x20 magnification in the 
hypothermia+fentanyl (left column) and hypothermia+dexmedetomidine (right column) in the 
putamen and white matter. B. There was an overall increase in the TUNEL-positive cells per 
mm2 (pooled across region and R0/R1 levels) in the hypothermia+dexmedetomidine 
compared to the hypothermia+fentanyl groups. C. On regional assessment, there was no 
significant difference between TUNEL positive cells across the 7 individual brain regions.  
 
Figure 6A. A visual predictive check was plotted for the dexmedetomidine pharmacokinetic 
(PK) model. All plots show median and 90% intervals (solid and dashed lines). The prediction 
corrected observed concentrations are plotted. With a bolus of 2 μg/kg dexmedetomidine 
over 20 minutes followed by an infusion of 0.028 μg/kg/h the concentration in most but not all 
subjects was below1μg/L. 
 
Figure 6B. Prediction corrected percentiles (10%, 50%, 90%) are shown for observations 
(lines with symbols) and predictions (lines) with 95% confidence intervals for prediction 
percentiles (gray shaded areas). 
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